# Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

> **NCT04065555** · EARLY_PHASE1 · COMPLETED · sponsor: **Presage Biosciences** · enrollment: 12 (actual)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** TAK-981
- **BIOLOGICAL:** Cetuximab
- **BIOLOGICAL:** Avelumab
- **COMBINATION_PRODUCT:** TAK-981 + Cetuximab
- **COMBINATION_PRODUCT:** TAK-981 + Avelumab

## Key facts

- **NCT ID:** NCT04065555
- **Lead sponsor:** Presage Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-07
- **Primary completion:** 2022-06-20
- **Final completion:** 2022-07-20
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04065555

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04065555, "Intratumoral Microdosing of TAK-981 in Head and Neck Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04065555. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*